PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION

por Dale, D. C., Alsina, L., Azar, A., Badolato, R., Bertrand, Y., Deya, A., Dickerson, K. E., Ezra, N., Hasle, H., Kang, H. J., Kiani-Alikhan, S., Kuijpers, T., Kulagin, A., Langguth, D., Levin, C., Neth, O., Peake, J., Rutten, C. E., Shcherbina, A., Tarrant, T. K., Vossen, M. G., Wysocki, C. A., Belschner, A., Cadavid, D., Hu, Y., Jiang, H., MacLeod, R., Tang, W., Tillinger, M., Donadieu, J.
Publicado 2022